Clinical Trials Logo

Filter by:
NCT ID: NCT00167128 Recruiting - Clinical trials for Auditory Processing Disorder

The Phonak EduLink-System in Students With Specific Performance Deficits in Speech-in-Noise Intelligibility

Start date: March 2005
Phase: N/A
Study type: Interventional

In the management and remediation of students with specific performance deficits in speech-in-noise intelligibility, most often, a "triad" approach for treatment is used, which includes direct therapy, compensatory strategies, and environmental modifications. The purpose of the study is to determine whether a new hearing aid, the Phonak EduLink-FM System, can improve specific performance deficits in speech-in-noise intelligibility. Participants will complete a test battery related to auditory processing, as well as some psychological tests and questionnaires. One group of participants with specific performance deficits in speech-in-noise intelligibility will receive the hearing aid for use in school; a second group will not. The effect of this treatment on auditory performance, school performance and satisfaction, attention and verbal learning and memory, self concept, behavior and listening effort following 26 weeks of hearing aid use will be compared across the groups.

NCT ID: NCT00161551 Recruiting - Sick Sinus Syndrome Clinical Trials

Mode Evaluation in Sick Sinus Syndrome Trial (MODEST)

Start date: November 2004
Phase: Phase 4
Study type: Interventional

The purpose of this study is to determine the incidence of atrial fibrillation and heart failure in patients with pacemaker therapy with different pacing modes (AAI, DDD, and a novel algorithm to minimize ventricular pacing).

NCT ID: NCT00160888 Recruiting - Healthy Clinical Trials

Vasoreactivity in Carriers of Genetic Polymorphisms

Start date: November 1999
Phase: Phase 1
Study type: Interventional

The objective of the study is to assess the impact of genetic variation (especially polymorphisms of the gene coding endothelial nitric oxide synthase (eNOS) and the bradykinin B2 receptor gene) on venous and arterial responsiveness to vasodilators in healthy individuals without cardiovascular risk factors.

NCT ID: NCT00154440 Recruiting - Lymphoma Clinical Trials

Helicobacter – Lymphoma – Radiation Part I: Eradication, Part II: Radiation

Start date: November 2001
Phase: Phase 3
Study type: Interventional

The first objective of this study is to confirm the results of complete remission of low-grade gastric MALT lymphoma stage IE & II1E after H. pylori eradication on a larger number of patients (HELYX Part I). If there is no response to the antibiotic therapy, the role of radiotherapy on the course of gastric MALT lymphoma will be investigated as a consecutive therapeutic option for patients that are H. pylori- negative, t(11;18)-positive or failure candidates after eradication therapy. Furthermore, the method of radiation, and the radiation dose will be investigated and standardized. HELYX PART II is therefore a randomized equivalent study comparing the standard dose of 36Gy vs. a reduced dose of 25.2Gy locoregional. Additional molecular genetic analysis will be performed to try to understand pathogenetic mechanisms of lymphomagenesis.

NCT ID: NCT00153608 Recruiting - Clinical trials for WT1 Expressing Carcinoma

WT1 Peptid Vaccination in Carcinomas

Start date: April 2004
Phase: Phase 2
Study type: Interventional

In this trial HLA-A2+ patients with WT1 expressing carcinomas are vaccinated with a peptide from the leukemia associated antigen WT1 together with immunological adjuvants KLH as T-helper protein and GM-CSF

NCT ID: NCT00153582 Recruiting - Clinical trials for Acute Myeloid Leukemia

WT1 Peptide Vaccination in Acute Myeloid Leukemia (AML)

Start date: April 2002
Phase: Phase 2
Study type: Interventional

In this trial, HLA-A2+ patients with active AML are vaccinated with a peptide from the leukemia-associated antigen WT1 together with immunological adjuvants keyhole limpet hemocyanin (KLH) as T-helper protein and granulocyte macrophage colony stimulating factor (GM-CSF) 4 times bi-weekly, then monthly.

NCT ID: NCT00148161 Recruiting - Stuttering Clinical Trials

Activity of the Auditory Cortex During Speech Perception and Speech Production in Stuttering

Start date: November 2004
Phase: N/A
Study type: Observational

The goal of the study is to examine the cortical activity during speech perception and speech production in idiopathic stutterers compared to fluent speakers. Therefore, the noninvasive method of magnetoencephalography (MEG) is used. A better understanding for the complexity of speech perception and its pathology should be developed. Fundamental properties of stuttering are repetitions, prolongations, and blocks. In most cases stuttering emerges between 2 and 5 years of age. The auditory feedback should become less important during development, as soon as information about mispronounced words does not occur anymore. During speech development this control function should be adopted by other systems. In stutterers the dominance of the acoustic control should remain. Brain imaging studies with positron emission tomography (PET) or magnetic resonance imaging (MRI) show defects in the network of motor system, in the lateralization of speech areas, and functions of the auditory cortex. Magnetoencephalographic studies describe a similar variety as cause of stuttering. There may be defects in the auditory feedback, a modification of the lateralization of speech areas, or an alteration of co-action of motor planning and auditory system. The benefit of magnetoencephalography is a very good temporal resolution in the range of milliseconds combined with good spatial resolution. Therefore, it is well suited to examine the dynamics of cortical processing during stuttering. In this study evoked components of the auditory systems related to complex sounds, vocals, consonant-vocal combinations, and single words are analyzed. Differences of these components in the auditory cortices of stutterers and fluent speakers are hypothesized as well in temporal structure as in localization and lateralization.

NCT ID: NCT00146276 Recruiting - Bladder Cancer Clinical Trials

Adjuvant Versus Progression-Triggered Gemcitabine Monotherapy for Locally Advanced Bladder Cancer

Start date: July 2000
Phase: Phase 3
Study type: Interventional

Primary Objective: - To analyse time to tumor progression in patients cystectomized for locally advanced transitional cell carcinoma (TCC) of the bladder, who are not suitable for cisplatin-based chemotherapy (i.e. postoperative reduced renal function, advanced age). Patients are randomized to receive either adjuvant gemcitabine immediately after radical operation (treatment arm A) or no treatment (control arm B). Patients in the control arm are to be treated with gemcitabine as soon as tumor progression becomes evident clinically and/or radiologically. Secondary Objectives: The secondary objectives of this study are: - Estimation of time-specific survival probabilities irrespective of causes of death. - Assessment of toxicity and tolerability of gemcitabine - Description of survival experience of patients in the control arm beyond the time of initiating chemotherapy. - Assessment of quality of life (European Organization for Research and Treatment of Cancer [EORTC] Quality of Life Questionnaire [QLQ]-C30). Study Design: This is an open-label, prospective, multicenter, randomized, controlled phase 3 two-arm study using gemcitabine as a single agent in chemonaive cystectomy patients with locally advanced TCC of the bladder in an adjuvant setting. The patients will receive the following treatment: Arm A (treatment): gemcitabine 1250 mg/m2 intravenously once a week for 2 weeks (days 1 and 8) followed by 1-week rest period. Repeat cycle on day 22. Maximum of 6 cycles. Begin treatment until 3 months after radical operation (within first 6 weeks is recommended). Arm B (control): No immediate post-surgery treatment. Watchful waiting; treatment only conditionally in case of progression with gemcitabine (dose and schedule as in arm A).

NCT ID: NCT00144794 Recruiting - Clinical trials for Mucopolysaccharidosis I (MPS I)

Mucopolysaccharidosis I (MPS I) Registry

Start date: November 20, 2003
Phase:
Study type: Observational

The Mucopolysaccharidosis I (MPS I) Registry is an ongoing, observational database that tracks the outcomes of patients with MPS I. The data collected by the MPS I Registry will provide information to better characterize the natural history and progression of MPS I as well as the clinical responses of patients receiving enzyme replacement therapy, such as Aldurazyme (Recombinant Human Alpha-L-Iduronidase), or other treatment modalities. The objectives of the Registry are: - To evaluate the long-term effectiveness and safety of Aldurazyme® (laronidase) - To characterize and describe the MPS I population as a whole, including the variability, progression, and natural history of MPS I - To help the MPS I medical community with the development of recommendations for monitoring patients and reports on patient outcomes to optimize patient care

NCT ID: NCT00132223 Recruiting - Epilepsy Clinical Trials

Effects on the Diagnostic Accuracy of Magnetic Imaging Angiographies of the Supra-Aortic Vessels by Three Different Magnetic Resonance Contrast Agents in Patients

Start date: April 2005
Phase: Phase 4
Study type: Interventional

Angiographies of the supra-aortic vessels by magnetic imaging have become common recently. So it was the purpose of this study to evaluate the imaging potential of different contrast agents. Three contrast agents for magnetic resonance imaging are compared in angiographies of the supra-aortic arteries in a intraindividual study of 10 patients. All applications of these contrast agents are performed with a flow of 2 ml/s. One contrast medium is applicated a second time with a reduced flow of 1 ml/s. The angiographies of the supra-aortic vessels are evaluated by two experienced readers in a consensus reading. The signal/noise- and contrast/noise-ratio of anatomic vessel segments of the carotic and vertebral arteries are measured and compared to each other.